ESMO Breast 2024 | REALITY-01: real-world use of trastuzumab deruxtecan in breast cancer
Jean-Yves Pierga, MD, PhD, Institut Curie, Paris, France, evaluates findings from the REALITY-01 study (NCT05149014) of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with HER2+ metastatic breast cancer, who had received at least two prior anti-HER2 treatments. Interim results indicate a promising median progression-free survival and objective response rate, with a favorable safety profile aligning with DESTINY-Breast01 (NCT03248492) and 02 (NCT03523585) results. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
